Suppr超能文献

心室辅助装置:历史、患者选择和治疗时机。

Ventricular assist devices: history, patient selection, and timing of therapy.

机构信息

Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA.

出版信息

J Cardiovasc Transl Res. 2009 Jun;2(2):159-67. doi: 10.1007/s12265-009-9098-5. Epub 2009 Mar 19.

Abstract

Timing of therapy and selection of patients in the use of ventricular assist devices (VADs) can be difficult. In general, consideration for VAD implantation is appropriate in patients with endstage heart failure who are failing optimal medical therapy and in whom no alternative traditional surgical treatment options are available. However, identifying when a particular patient has reached this point is not always straightforward. There are a broad range of medical and surgical therapies for patients with overt heart failure, and this armamentarium is constantly expanding. The risks, benefits, and expected outcomes with VAD therapy have also undergone dramatic changes over the last decade. Advances in technology have led to a proliferation of newer generation devices that are smaller, lighter, easier to implant, and more reliable than previous generation devices. This, in turn, has led to a markedly improved risk-benefit ratio, with increased durability and reduced morbidity. The indications for the implantation of ventricular assist devices have also evolved over the last several years, and specific patient presentations and goals of therapy have led to specific indications. Device therapy has traditionally been classified as bridge to recovery, bridge to transplantation, and destination therapy. However, such designations may not be well defined at the time of implantation, and recovery and response following initiation of VAD support may allow patients to change from one classification to another. The current data regarding indications and timing of device implantation are reviewed.

摘要

在使用心室辅助装置(VAD)时,治疗时机和患者选择可能会比较困难。一般来说,对于正在接受最佳药物治疗但心力衰竭已发展至终末期且没有其他传统手术治疗选择的患者,可以考虑植入 VAD。然而,要确定特定患者是否已达到这一点并不总是那么简单。对于有明显心力衰竭的患者,有广泛的药物和手术治疗方法,而且这个治疗方法库还在不断扩大。过去十年中,VAD 治疗的风险、益处和预期结果也发生了巨大变化。技术的进步导致了新一代更小、更轻、更容易植入和更可靠的设备的大量涌现,这反过来又带来了明显改善的风险效益比,提高了耐用性并降低了发病率。过去几年中,VAD 植入的适应证也发生了演变,特定的患者表现和治疗目标导致了特定的适应证。传统上,设备治疗被分为恢复桥接、移植桥接和终末期治疗。然而,在植入时,这些指定可能并不明确,并且在开始 VAD 支持后,患者的恢复和反应可能会使他们从一种分类转变为另一种分类。本文回顾了设备植入的适应证和时机的相关数据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验